Dr. John Ligon works to treat children and young adults with cancer and blood disorders. Dr. Ligon is board-certified in general pediatrics and pediatric hematology and oncology by the American Board of Pediatrics. Dr. Ligon is a member of numerous professional societies, including the Children’s Oncology Group and the American Association for Cancer Research.
Areas of Expertise (10)
Fertility and CAR T-cells: Current practice and future directionsTransplantation and Cellular Therapy
John A.Ligon, et. al
Chimeric antigen receptor (CAR) T-cells serve to overcome chemotherapeutic resistance and have been proven to be highly effective in B-cell hematologic malignancies. Although initial use has been in patients with multiply relapsed/refractory disease, as CAR T-cells are used earlier in the treatment paradigm, it will be important to explore implications of this novel therapy on cancer late-effects.
The Impact of Race, Ethnicity, and Obesity on CAR T-cell Therapy OutcomesBlood Advances
Aiman J.Faruqi, et. al
Cancer outcomes with chemotherapy are inferior in patients of minority racial/ethnic groups and those with obesity. Chimeric antigen receptor (CAR) T-cell therapy has transformed outcomes for relapsed/refractory hematologic malignancies, but whether its benefits extend commensurately to racial/ethnic minorities and patients with obesity is poorly understood.
Reporting of Racial and Ethnic Minority Representation in Early Phase Pediatric Oncology Clinical TrialsThe Oncologist
Aiman J Faruqi, et. al
Racial and ethnic minorities face systemic barriers to equitable representation in clinical trials. Snapshot data from the United States (US) Food and Drug Administration has shown Black and African American patients comprised less than 10% of study populations for clinical trials spanning from 2015 to 2020, which contrasts significantly from the current demographic landscape in the US.
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapyBlood Advances
Elizabeth M. Holland, et. al
Chimeric antigen receptor T cells effectively eradicate medullary B-cell acute lymphoblastic leukemia and can traffic to and clear central nervous system involvement. CAR T-cell activity in non-CNS extramedullary disease has not been well characterized. We systematically evaluated CAR T-cell kinetics, associated toxicities and efficacy in B-ALL non-CNS EMD. We conducted a retrospective review of B-ALL patients with non-CNS EMD who were screened for/enrolled on one of three CAR trials at our institution.